Pharmacokinetics and Pharmacodynamics of Intravenous Inotropic Agents
Tóm tắt
Positive inotropic drugs have various mechanisms of action. Long-term use of cyclic adenosine monophosphate (cAMP)-dependent drugs has adverse effects on the prognosis of heart failure patients, whereas digoxin has neutral effect on mortality. There are, however, little data on the effects of intravenous inotropic drugs on the outcome of patients. Intravenous inotropic agents are used to treat cardiac emergencies and refractory heart failure. β-Adrenergic agonists are rapid acting and easy to titrate, with short elimination half-life. However, they increase myocardial oxygen consumption and are thus hazardous during myocardial ischaemia. Furthermore they may promote myocyte apoptosis. Phosphodiesterase (PDE) III inhibiting drugs (amrinone, milrinone and enoximone) increase contractility by reducing the degradation of cAMP. In addition, they reduce both preload and afterload via vasodilation. Short-term use of intravenous milrinone is not associated with increased mortality, and some symptomatic benefit may be obtained when it is used in refractory heart failure. Furthermore, PDE III inhibitors facilitate weaning from the cardiopulmonary bypass machine after cardiac surgery. Levosimendan belongs to a new group of positive inotropic drugs, the calcium sensitisers. It has complex pharmacokinetics and long-lasting haemodynamic effects as a result of its active metabolites. In comparative trials, it has been better tolerated than the most widely used β-agonist inotropic drug, dobutamine. The pharmacokinetics of the intravenous inotropic drugs might sometimes greatly modify and prolong the response to the therapy, for example because of long-acting active metabolites. These drugs display considerable differences in their pharmacokinetics and pharmacodynamics, and the selection of the most appropriate inotropic drug for each patient should be based on careful consideration of the clinical status of the patient and on the pharmacology of the drug.
Tài liệu tham khảo
Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001 Dec; 38(7): 2101–13
Felker GM, O’Connor CM. Rational use of inotropic therapy in heart failure. Curr Cardiol Rep 2001 Mar; 3(2): 108–13
Singh K, Xiao L, Remondino A, et al. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 2001 Dec; 189(3): 257–65
Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002 Feb 6; 287(5): 628–40
Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 1998; 41: 207–24
Feldman AM. Classification of positive inotropic agents. J Am Coll Cardiol 1993 Oct; 22(4): 1223–7
Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991 Nov 21; 325(21): 1468–75
Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996 Sep; 76(3): 223–31
Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure: Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997 Apr 5; 349(9057): 971–7
Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators. N Engl J Med 1998 Dec 17; 339(25): 1810–6
Moe GW, Rouleau JL, Charbonneau L, et al. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am Heart J 2000 Apr; 139(4): 587–95
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997 Feb 20; 336(8): 525–33
Moiseyev V, Pöder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitiser, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002 Sep 15; 23(18): 1422–32
Lehtonen LA. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs 2001 May; 10(5): 955–70
Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986 Sep; 59(3): 297–309
Goldberg LI. Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1989; 14 Suppl. 8: S21–8
Silver PJ. Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase. Am J Cardiol 1989 Jan 3; 63(2): 2A–8A
Harrison SA, Chang ML, Beavo JA. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs. Circulation 1986 Mar; 73 (3 Pt 2): III109–16
Lugnier C, Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J 1993 Nov; 14 Suppl. I: 141–8
Vroom M. Pharmacologial and clinical aspects of inotropic agents used in the management of acute heart failure: academic dissertation. Amsterdam: Academic Medical Center, 1996
Lugnier C, Keravis T, Eckly-Michel A. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel. J Physiol Pharmacol 1999 Dec; 50(4): 639–52
Katz AM. Effects of digitalis on cell biochemistry: sodium pump inhibition. J Am Coll Cardiol 1985 May; 5(5 Suppl. A): 16A–21A
Chaudhry GM, Haffajee CI. Antiarrhythmic agents and proarrhythmia. Crit Care Med 2000 Oct; 28 (10 Suppl.): N158–64
Reiffel JA, Bigger Jr JT, Cramer M. Effects of digoxin on sinus nodal function before and after vagai blockade in patients with sinus nodal dysfunction: a clue to the mechanisms of the action of digitalis on the sinus node. Am J Cardiol 1979 May; 43(5): 983–9
Gonzalez MD, Vassalle M. Role of oscillatory potential and pacemaker shifts in digitalis intoxication of the sinoatrial node. Circulation 1993 May; 87(5): 1705–14
Lehtonen L. Levosimendan: a promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep 2000 May; 2(3): 233–43
Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: a molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994 Nov 18; 269(46): 28584–90
Haikala H, Kaivola J, Nissinen E, et al. Cardiac Troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995 Sep; 27(9): 1859–66
Kleerekoper Q, Putkey JA. Drug binding to cardiac troponin C. J Biol Chem 1999 Aug 20; 274(34): 23932–9
Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001; 276: 9337–43
Brouwer J, van Veldhuisen DJ, Manin’t Veld AJ, et al. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine: the Dutch Ibopamine Multicenter Trial (DIMT) Study Group. J Am Coll Cardiol 1995 Oct; 26(4): 983–90
Tanigawara Y. Role of P-glycoprotein in drag disposition. Ther Drug Monit 2000 Feb; 22(1): 137–40
Leier CV, Binkley PF. Acute positive inotropic intervention: the catecholamines. Am Heart J 1991 Jun; 121(6 Pt 1): 1866–70
Steinberg C, Notterman DA. Pharmacokinetics of cardiovascular drags in children: inotropes and vasopressors. Clin Pharmacokinet 1994 Nov; 27(5): 345–67
Fisher DG, Schwartz PH, Davis AL. Pharmacokinetics of exogenous epinephrine in critically ill children. Crit Care Med 1993 Jan; 21(1): 111–7
Klem C, Dasta JF, Reilley TE, et al. Variability in dobutamine pharmacokinetics in unstable critically ill surgical patients. Crit Care Med 1994 Dec; 22(12): 1926–32
Fitton A, Benfield P. Dopexamine hydrochloride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drags 1990 Feb; 39(2): 308–30
Le Corre P, Malledant Y, Tanguy M, et al. Steady-state pharmacokinetics of dopamine in adult patients. Crit Care Med 1993 Nov; 21(11): 1652–7
Onasch A, Tanzeem A, Isgro F, et al. Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18h after infusion. Eur J Clin Pharmacol 2000 Jan; 55(10): 755–9
Juste RN, Moran L, Hooper J, et al. Dopamine clearance in critically ill patients. Intensive Care Med 1998 Nov; 24(11): 1217–20
Levy JH, Bailey JM. Amrinone: pharmacokinetics and pharmacodynamics. J Cardiothorac Anesth 1989 Dec; 3 (6 Suppl. 2): 10–4
Kullberg MP, Freeman GB, Biddlecome C, et al. Amrinone metabolism. Clin Pharmacol Ther 1981 Mar; 29(3): 394–401
Hamilton RA, Kowalsky SF, Wright EM, et al. Effect of the acetylator phenotype on amrinone pharmacokinetics. Clin Pharmacol Ther 1986 Dec; 40(6): 615–9
Dage RC, Okerholm RA. Pharmacology and pharmacokinetics of enoximone. Cardiology 1990; 77 Suppl. 3: 2–13
Okerholm RA, Chan KY, Lang JF, et al. Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite. Am J Cardiol 1987 Aug 14; 60(5): 21C–6C
Benotti JR, Lesko LJ, McCue JE, et al. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol 1985 Oct 1; 56(10): 685–9
Bailey JM, Levy JH, Kikura M, et al. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology 1994 Sep; 81(3): 616–22
Ochs HR, Greenblatt DJ, Bodem G. Single- and multiple-dose kinetics of intravenous digoxin. Clin Pharmacol Ther 1980 Sep; 28(3): 340–5
Sandell EP, Häyhä M, Antila S, et al. Pharmacokinetics of levosimendan in healthy volunteers and in patients with congestive heart failure. J Cardiovasc Pharmacol 1995; 26 Suppl. 1: S57–62
Antila S, Järvinen A, Honkanen T, et al. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitizer levosimendan and warfarin. Eur J Clin Pharmacol 2000 Dec; 56(9–10): 705–10
Kivikko M, Antila S, Eha J, et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002 Jan; 42(1): 43–51
Pentikäinen PJ, Antila S, Kivikko M, et al. Pharmacokinetics of levosimendan in patients with severe congestive heart failure [abstract]. J Card Fail 1999; 5 Suppl 1; 48
Banner Jr W, Vernon DD, Minton SD, et al. Nonlinear dobutamine pharmacokinetics in a pediatric population. Crit Care Med 1991 Jul; 19(7): 871–3
Habib DM, Padbury JF, Anas NG, et al. Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Crit Care Med 1992 May; 20(5): 601–8
Ratge D, Steegmuller U, Mikus G, et al. Dopamine infusion in healthy subjects and critically ill patients. Clin Exp Pharmacol Physiol 1990 May; 17(5): 361–9
Notterman DA, Greenwald BM, Moran F, et al. Dopamine clearance in critically ill infants and children: effect of age and organ system dysfunction. Clin Pharmacol Ther 1990 Aug; 48(2): 138–47
Edelson J, LeJemtel TH, Alousi AA, et al. Relationship between amrinone plasma concentration and cardiac index. Clin Pharmacol Ther 1981 Jun; 29(6): 723–8
Ross MP, Allen-Webb EM, Pappas JB, et al. Amrinoneassociated thrombocytopenia: pharmacokinetic analysis. Clin Pharmacol Ther 1993 Jun; 53(6): 661–7
Allen-Webb EM, Ross MP, Pappas JB, et al. Age-related amrinone pharmacokinetics in a pediatrie population. Crit Care Med 1994 Jun; 22(6): 1016–24
Laitinen P, Ahonen J, Olkkola KT, et al. Pharmacokinetics of amrinone in neonates and infants. J Cardiothorac Vasc Anesth 2000 Aug; 14(4): 378–82
Hellinger A, Wolter K, Marggraf G, et al. Elimination of amrinone during continuous veno-venous haemofiltration after cardiac surgery. Eur J Clin Pharmacol 1995; 48(1): 57–9
Bailey JM, Levy JH, Rogers HG, et al. Pharmacokinetics of amrinone during cardiac surgery. Anesthesiology 1991 Dec; 75(6): 961–8
Burns AM, Park GR. Prolonged action of enoximone in renal failure. Anaesthesia 1991 Oct; 46(10): 864–5
Fiegel P, Trenk D, Jaehnchen E, et al. Pharmacokinetics of intravenous enoximone in dialysis patients. J Cardiovasc Pharmacol 1989; 14 Suppl. 1: S20–3
Booker PD, Gibbons S, Stewart JI, et al. Enoximone pharmacokinetics in infants. Br J Anaesth 2000 Aug; 85(2): 205–10
Woolfrey SG, Hegbrant J, Thysell H, et al. Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. J Pharm Pharmacol 1995 Aug; 47(8): 651–5
Taniguchi T, Shibata K, Saito S, et al. Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. Intensive Care Med 2000 Aug; 26(8): 1089–93
Bailey JM, Miller BE, Lu W, et al. The pharmacokinetics of milrinone in pediatrie patients after cardiac surgery. Anesthesiology 1999 Apr; 90(4): 1012–8
Iisalo E. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 1977 Jan-Feb; 2(1): 1–16
Turanlahti M, Antila S, Rantanen S, et al. Pharmacokinetics and safety profile of levosimendan in pediatrie patients evaluated for cardiac surgery [abstract no. 270]. Intensive Care Med 1999; 25 Suppl. 1: S72
Sandell E, Antila S, Koistinen H, Pentikäinen P. The effects of renal failure on the pharmacokinetics of levosimendan [abstract]. Therapie 1995: 50 Suppl. 1; A495
Edelson J, Stroshane R, Benziger DP, et al. Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation 1986 Mar; 73 (3 Pt 2): III145–52
Baruch L, Patacsil P, Hameed A, et al. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J 2001 Feb; 141(2): 266–73
Vernon MW, Heel RC, Brogden RN. Enoximone: a review of its pharmacological properties and therapeutic potential. Drugs 1991 Dec; 42(6): 997–1017
Smith NA, Kates RE, Lebsack C, et al. Clinical pharmacology of intravenous enoximone: pharmacodynamics and pharmacokinetics in patients with heart failure. Am Heart J 1991 Sep; 122 (3 Pt 1): 755–63
Endoh M. Mechanism of action of Ca2+ sensitizers: update 2001. Cardiovasc Drugs Ther 2001 Sep; 15(5): 397–403
Antila S, Jarvinen A, Akkila J, et al. Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol. Arzneimittelforschung 1997 Jul; 47(7): 816–20
Sundberg S, Antila S, Scheinin H, et al. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther 1998 Dec; 36(12): 629–35
Antila S. Pharmacokinetics of a new calcium sensitizer levosimendan with special reference to pharmacodynamics and potential drug interactions [academic dissertation]. Kuopio, Finland: Kuopio University, 2001
Pagel P, Haikala H, Pentikäinen P, et al. Pharmacology of levosimendan: a new myofilament calcium sensitizer. Cardiovasc Drug Rev 1996; 14(3): 286–316
Antila S, Huuskonen H, Nevalainen T, et al. Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 1999 Oct; 9(1): 85–91
Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol 2000 Jul 14; 400(1): 103–12
Takahashi R, Talukder MA, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 2000 Jul; 36(1): 118–25
Jonsson EN, Antila S, McFadyen L, et al. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol 2003; 55: 544–51
Remme WJ, van Hoogenhuyze DC, Kruijssen HA, et al. Preload-dependent hemodynamic effects of milrinone in moderate heart failure. Cardiology 1992; 80(2): 132–42
Pousset F, Chalon S, Thomare P, et al. Evaluation of cardiac beta 1-adrenergic sensitivity with dobutamine in healthy volunteers. Br J Clin Pharmacol 1995 Jun; 39(6): 633–9
Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000 Nov 15; 36(6): 1903–12
Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000 Nov; 68(5): 522–31
Leier CV, Heban PT, Huss P, et al. Comparative systemic and regional hemodynamic effect of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978 Sep; 58(3): 466–75
Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000 Oct 31; 102(18): 2222–7
Lilleberg J, Sundberg S, Nieminen MS. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995; 26 Suppl. 1: S63–9
Lang R. Medical management of chronic heart failure: inotropic, vasodilator, or inodilator drugs? Am Heart J 1990 Dec; 120 (6 Pt 2): 1558–64
Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001 Sep; 142(3): 393–401
Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002 Mar 6; 39(5): 798–803
Follath F, Hinkka S, Jäger D, et al. Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial. Am J Cardiol 1999; 83 Suppl. 12B: S21–5
Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002 Jul 20; 360(9328): 196–202
Gundert-Remy U, Penzien J, Hildebrandt R, et al. Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. Eur J Clin Pharmacol 1984; 26(2): 163–9
Janssen PM, Datz N, Zeitz O, et al. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 2000 Sep 15; 404(1–2): 191–9
Brixius K, Reicke S, Schwinger RH. Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 2002 Jan; 282(1): H131–7
Committee for Proprietary Medical Products. CPMP/EWP/235/95: note for guidance on the clinical investigation of medicinal products in the treatment of cardiac failure. Rev. 1. London: Committee for Proprietary Medical Products, 1999
United States Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Division of Cardio-Renai Drug Products. Transcripts of cardiovascular and renal drugs advisory committee 87th meeting, 1999 Jan 29 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3490t2.rtf [Accessed 2003 Dec 16]
Cuffe MS, Califf RM, Adams KF, et al. Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J 2000 Jan; 139 (1 Pt 1): 15–22
Cuffe MS, Califf RM, Adams Jr KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002 Mar 27; 287(12): 1541–7
Yamani MH, Haji SA, Starling RC, et al. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy, clinical outcome, and economic impact. Am Heart J 2001 Dec; 142(6): 998–1002
Loh E, Elkayam U, Cody R, et al. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail 2001 Jun; 7(2): 114–21
Karlsberg RP, DeWood MA, DeMaria AN, et al. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction: Milrinone-Dobutamine Study Group. Clin Cardiol 1996 Jan; 19(1): 21–30
DiSesa VJ, Gold JP, Shemin RJ, et al. Comparison of dopamine and dobutamine in patients requiring postoperative circulatory support. Clin Cardiol 1986 Jun; 9(6): 253–6
MacGregor DA, Butterworth IV JF, Zaloga CP, et al. Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 1994 Sep; 106(3): 835–41
Dupuis JY, Bondy R, Cattran C, et al. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. J Cardiothorac Vasc Anesth 1992 Oct; 6(5): 542–53
Rathmell JP, Prielipp RC, Butterworth JF, et al. A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery. Anesth Analg 1998 Apr; 86(4): 683–90
Feneck RO. Intravenous milrinone following cardiac surgery. I: effects of bolus infusion followed by variable dose maintenance infusion: The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth 1992 Oct; 6(5): 554–62
Feneck RO. Intravenous milrinone following cardiac surgery. II: influence of baseline hemodynamics and patient factors on therapeutic response: The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth 1992 Oct; 6(5): 563–7
Doolan LA, Jones EF, Kaiman J, et al. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997 Feb; 11(1): 37–41
Tarr TJ, Jeffrey RR, Kent AP, et al. Use of enoximone in weaning from cardiopulmonary bypass following mitral valve surgery. Cardiology 1990; 77 Suppl. 3: 51–7
Yamada T, Takeda J, Katori N, et al. Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index. J Cardiothorac Vasc Anesth 2000 Aug; 14(4): 367–73
Birnbaum DE, Preuner JG, Gieseke R, et al. Enoximone versus dopamine in patients being weaned from cardiopulmonary bypass. Cardiology 1990; 77 Suppl. 3: 34–41
Boldt J, Knothe C, Zickmann B, et al. The role of enoximone in cardiac surgery. Br J Anaesth 1992 Jul; 69(1): 45–50
Nijhawan N, Nicolosi AC, Montgomery MW, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999 Aug; 34(2): 219–28
Lehtonen L, Mills-Owens P, Akkila J. Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol 1995; 26 Suppl. 1: S70–6
Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995 Sep-Oct; 38(2): 167–80
Bristow MR, Shakar SF, Linseman JV, et al. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail 2001 Jun; 7 (2 Suppl. 1): 8–12